Changes Following Parathyroidectomy in Hemodialyzed Patients

  • Y. Berland
  • S. Charhon
  • M. Olmer
  • P. J. Meunier
Chapter
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 178)

Abstract

Secondary hyperparathyroidism (HPT) remains a frequent complication of chronic renal failure (CRF) despite a better understanding of the factors responsible for its development (1). A prolonged survival of the patients by dialysis results in a growing number of uremics who present with severe HPT responsible not only for major bone lesions but also for an impairment of different vital functions (2). The metabolites of vitamin D such a 1,25 dihydroxycholecalciferol that can play a preventive role in renal osteodystrophy at an early stage of chronic renal failure (3) are inconsistently effective and difficult to handle during severe HPT (4). Thus, treatment by parathyroidectony (PTX) appears sometimes to be required (5).

Keywords

Chronic Renal Failure Calcification Rate Renal Osteodystrophy Osteitis Fibrosa Subtotal Parathyroidectomy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    J.W. Coburn, Renal osteodystrophy, Kidney Internat. 17: 677–693, 1980.CrossRefGoogle Scholar
  2. 2.
    S.G. Massry, D.A. Goldstein, The search for uremic toxin (s) “X” “x” = PTH, Clin. Nephrol. 11: 181–189, 1979.Google Scholar
  3. 3.
    M.D. Healy, H.H., Malluche, D.A. Goldstein, F.R. Singer, S.G. Massry, Effects of long-term therapy with calcitriol in patients with moderate renal failure, Arch. Int. Med. 140: 1030–1033, 1980.Google Scholar
  4. 4.
    J.C. Prior, E.C. Cameron, H.S. Ballon, D.S. Lirenman, M.V. Moriarty, J.D.E. Price, Experience with 1,25 dihydroxychole-calciferol therapy in hemodialysis patients with progressive Vit D2 treated osteodystrophy, Am. J. Med. 67: 583–587, 1979.PubMedCrossRefGoogle Scholar
  5. 5.
    J.A. Diaz-Boxo, W.T. Geissinger, P.J. Walker, J.T. Chandler, C.D. Farmer, K.L. Holt, P. Wolfe, Total parathyroidectomy and autotransplantation, Clin. Nephrol. 16: 276–282, 1981.Google Scholar
  6. 6.
    R.S. Weinstein, Decreased mineralization in hemodialysis patients after subtotal parathyroidectomy, Calcif. Tis. Int. 34: 16–20, 1982.CrossRefGoogle Scholar
  7. 7.
    A.J. Felsenfeld, J.M. Harrelson, R.A. Gutman, S.A. Wells, M.K. Drezner, Osteomalacia after parathyroidectomy in patients with uremia, Ann. Intern. Med. 96: 34–39, 1982.PubMedGoogle Scholar
  8. 8.
    J. Zingraff, T. Drueke, J. Gueris, P. Jungers, J. Crosnier, Severe osteomalacia after subtotal parathyroidectomy in chronic uremic patients. Kidney Internat. 14: 204, 1978.Google Scholar
  9. 9.
    P.J. Meunier, C. Bressot, Endocrine influences on bone cells and bone remodeling evaluated by clinical histomorphometry. Endocrinology of calcium metabolism, Edited by John A. Parsons. Raven Press, New York, 445–465, 1982.Google Scholar
  10. 10.
    P.J. Meunier, P. Courpron, Iliac trabecular bone in 236 controls. Representativeness of iliac samples in bone morphometry. Ed. Z.F.G. Jaworski Univ. Ottawa. Press Ottawa: 100–105, 1976.Google Scholar
  11. 11.
    P.J. Meunier, C. Edouard, C. Bressot, J.N. Valat, P. Courpron,, P. Zech, Histomorphometrie osseuse dans l’insuffisance renale aigue et chronique, J. Urol. Nephrol. 81: 931–940, 1975.Google Scholar
  12. 12.
    P.J. Meunier, C. Edouard, P. Courpron, F. Toussaint, Morpho-metric analysis of osteoid in iliac trabecular bone methodology, Dynamical significance of the osteoid in iliac trabecular bone methodology. Dynamical significance of the osteoid parameters. In: Vitamin D and problems related to uremic bone disease. Ed. by A.W. Norman, K. Schaefe, H.G. Grigoleit, D.V. Herrath, E. Ritz, Walter de Groyter, Berlin: 149–155, 1975.Google Scholar
  13. 13.
    F. Melsen and L. Mosekilde, Tetracycline double-labeling of iliac trabecular bone in 41 normal adults, Calcif. Tiss. Res. 26: 99–102, 1978.CrossRefGoogle Scholar
  14. 14.
    N.A. Maloney, S.M. Ott, A.C. Alfrey, N.L. Miller, J.W., Coburn, D.J. Sherrard, Histological quantitation of aluminium in iliac bone from patients with renal failure, J. Lab. Clin. Med. 99: 206–216, 1982.PubMedGoogle Scholar
  15. 15.
    M.R. Buchanan, B.U. Ihle, C.M. Dunn, Haemodialysis related osteomalacia: A staining method to demonstrate aluminium. J. Clin. Pathol. 34: 1352–1354, 1981.PubMedCrossRefGoogle Scholar
  16. 16.
    P.J. Meunier, C. Edouard, P. Courpron, Morphometric analysis of trabecular resorption surfaces in normal iliac bone, In: Bone morphometry, Ed. Z.F.G. Jaworski, 156–160 University of Ottawa Press, Ottawa, 1976.Google Scholar
  17. 17.
    P.J. Meunier, P. Courpron, C. Edouard, C. Alexandre, C. Bressot, P. Lips, B.F. Boyce, Bone histomorphometry in osteoporotic states, In: Osteoporosis II, Ed. V.S. Barrel; 27–47 Grune and Stratton, New York, 1978.Google Scholar
  18. 18.
    S.L. Teitelbaum, M.A. Bengfeld, J. Freitag, K.A. Hruska, E. Slatopolsky, Do parathyroid hormone and 1,25 dihydroxyvitamin D modulate bone formation in uremia ? J. Clin. Endocrinol. Metab. 51: 247–251, 1980.PubMedCrossRefGoogle Scholar
  19. 19.
    A.M. Paritt, The coupling of bone formation to bone resorption: A critical analysis of the concept and of its relevance to the pathogenesis of osteoporosis. Metab. Bone. Dis. and Rel. Res. 4: 1–6, 1982.CrossRefGoogle Scholar
  20. 20.
    G.A. Howard, B.L. Bottemiller, D.J. Baylink, Evidence for the coupling of bone formation to bone resorption in vitro. Metab. Bone Dis. Rel. Res. 2: 131–135, 1980.CrossRefGoogle Scholar
  21. 21.
    J. Wergedal, M. Stauffer, D. Baylink, C. Rich, Inhibition of bone matrix formation, mineralization and resorption in thy-roparathyroidectomized rats, J. Clin. Invest. 52: 1052–1058, 1973.PubMedCrossRefGoogle Scholar
  22. 22.
    M.K. Dresner, F.A. Neelon, J. Jowsey, H.E. Lebovitz, Hypoparathyroidism: A possible cause of osteomalacia, J. Clin. Endocrinol. Metab. 45: 114–122, 1977.CrossRefGoogle Scholar
  23. 23.
    G. Cournot-Witmer, J. Zingraff, J.J. Plachot, F. Escaig, R. Lefevre, P. Boumati, A. Bourdeau, M. Garabedian, P. Galle, R. Bourdon, T. Drueke, S. Balsan, Aluminium localization in bone from hemodialysed patients: Relationship to matrix mineralization, Kidney Internat. 20: 375–385, 1981.CrossRefGoogle Scholar
  24. 24.
    H.A. Ellis, Aluminium and osteomalacia after parathyroidectomy, Ann. Intern. Med. 96: 533–534, 1982.PubMedGoogle Scholar
  25. 25.
    M.K. Ward, H.A. Ellis, T.G. Feest, I.S. Parkinson, D.N.S. Kerr, J. Herrington, G.L. Goode, Osteomalacic dialysis osteodystrophy: Evidence for a water-bone aetiological agent, probably aluminium, The Lancet. 1: 841–845, 1978.CrossRefGoogle Scholar
  26. 26.
    A. Fournier, P. Bordier, J. Gueris, J.L. Sebert, P.M. Ferriere, J. Bedrossian, H.F. De Luca, Comparison of 1-a-hydroxycholecalciferol in the treatment of renal osteodystrophy: Greater effect of 25-hydroxycholecalciferol on bone mineralization, Kidney Internat. 15: 196–204, 1979.CrossRefGoogle Scholar
  27. 27.
    P. Bordier, J. Zingraff, J. Gueris, P. Jungers, P. Marie, M. Pechet, H. Rasmussen, The effect of 1-a0HD3 and la25 0H2D3 on the bone in patients with renal osteodystrophy, Am. J. Med. 64: 101–107, 1978.PubMedCrossRefGoogle Scholar
  28. 28.
    H.E. Nielsen, F. Melsen, M.S. Christensen, H.E. Hansen, P. Rodbro, A. Johannsen, 1a-hydroxycholecalciferol treatment of long-term hemodialyzed patients. Effects of mineral metabolism, bone mineral content and bone morphometry, Clin. Nephrol. 8: 429–434, 1977.Google Scholar
  29. 29.
    A.M. Pierides, H.A. Ellis, W. Simpson, J.H. Denar, M.K. Ward, D.N.S. Kerr, Variables response to long-term laOHD3 in hemodialysis osteodystrophy, Lancet 1: 1092–1095, 1086.Google Scholar
  30. 30.
    K.Y. Ahmed, M.R. Wills, Z. Varghese, E.A. Meinhard, J.F. Moorhead, Long-term effects of small doses of 1,25 dihydroxycholecalciferol in renal osteodystrophy, Lancet 1: 629–632, 1978.PubMedCrossRefGoogle Scholar
  31. 31.
    J.B. Eastwood, T.C.B. Stamp, H.E. de Wardener, P.J. Bordier, C.D. Arnaud, The effect of 25-hydroxyvitamin D3 in the osteomalacia of chronic renal failure, Clin. Sci. Mol. Med. 52: 499–508, 1977.PubMedGoogle Scholar
  32. 32.
    S.L. Teitelbaum, J.M. Bone, P.M. Stein, J.J. Gilden, M. Bates, V.C. Boisseau, L.V. Avioli, Calcifediol in chronic renal insufficiency skeletal response, JAMA, 235: 164–167, 1976.PubMedCrossRefGoogle Scholar
  33. 33.
    H.M. Frost, D.L. Griffith, W.S.S. Jee, D.B. Kimmel, R.P. Mc Candlis, S.L. Teitelbaum, Histomorphometric changes in trabecular bone of renal failure patients treated with calcifediol. Metab. Bone Dis, and Rel. Res. 2: 285–295, 1981.Google Scholar

Copyright information

© Plenum Press, New York 1984

Authors and Affiliations

  • Y. Berland
    • 1
  • S. Charhon
    • 2
  • M. Olmer
    • 1
  • P. J. Meunier
    • 2
  1. 1.Service de NephrologieHopital de la ConceptionMarseilleFrance
  2. 2.Inserm U 234LyonFrance

Personalised recommendations